Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. - sprookjes - yvandenbroek - TriplyDB

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.

http://www.wikidata.org/entity/Q27863360

about

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?Fluoropyrimidine Activity Virtual Clinical Studies to Examine the Probability Distribution of the AUC at Target Tissues Using Physiologically-Based Pharmacokinetic Modeling: Application to Analyses of the Effect of Genetic Polymorphism of Enzymes and Transporters on Irinotec Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Polymorphisms in RAD51, XRCC2 and XRCC3 genes of the homologous recombination repair in colorectal cancer--a case control study.Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer Polymorphisms in XPD and ERCC1 Associated with Colorectal Cancer Outcome The aspartate aminotransferase to platelet ratio before chemotherapy predicts adverse events for FOLFOX and XELOX regimens including bevacizumab as the first-line therapy for stage IV, recurrent and metastatic colorectal cancer.Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy.Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity Tumor site- and stage-specific associations between allelic variants of glutathione S-transferase and DNA-repair genes and overall survival in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy Pharmacogenetic relevance of MTHFR polymorphisms.Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.Review of biomarkers in colorectal cancer.Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.Mahanine synergistically enhances cytotoxicity of 5-fluorouracil through ROS-mediated activation of PTEN and p53/p73 in colon carcinoma.PharmGKB summary: fluoropyrimidine pathways MTHFR gene polymorphisms and response to chemotherapy in colorectal cancer: a meta-analysis.

P2860

Q27851470-332BBD53-BBEE-4808-9F63-AA7DB379ABBF Q27851574-08A19FAC-AB04-451E-AC8D-41B2AC745594 Q28068930-D1BA956B-656F-41C8-8895-21C3B4354F74 Q28534572-7DA3E7AC-B4B0-4A70-B2DF-1629913DA667 Q28554294-6D397E46-757B-41C0-A2A2-DE42B5A7C543 Q29883401-0D7CE970-CC98-470A-B6FD-109DC59DB93A Q33875931-15873C3A-705C-41BC-934E-9EA3378F9B22 Q34008793-435BF17E-FE54-4E91-94A7-FA9AF3482F13 Q34274096-12F7D606-DB64-466B-8770-D645EADA1D30 Q34565071-AA599256-42DC-4E2A-BE68-72618F82133E Q34629650-4C89AFF2-B84F-4D2C-BB5C-510B33B92E8E Q34768474-2E528CB0-E6EA-482C-979F-04680AC3D76E Q35109800-B8663F07-C793-450F-A584-60835BE761C4 Q35623320-5201522A-4EEB-4431-86DE-1A870AFCB495 Q35742555-3A0C318F-7A2B-4F0D-B740-BE749A891D6F Q36135372-5058E48E-D4D8-49D8-A76D-1D729D476797 Q36656187-2B10114F-DA0A-47AB-8BAE-7EF4085167E2 Q36792350-809BA684-D0C7-480A-B079-70C340C63092 Q36859220-1BAA25F7-651E-4B52-85F9-09ED77A7F617 Q36959145-D6DA955C-6765-4199-92AF-5E4D5AF26786 Q37039153-FB46E3E8-029F-434D-821F-40D0578FFA1C Q37264528-65469147-AE11-4EC9-91F2-D6EC33155042 Q37345347-FAEEF736-D36D-48ED-BAF4-CFD07F4B83F1 Q37383249-32A231E9-D251-41CD-A726-C51A8751B3A8 Q37471631-B5E58E34-D0A8-439E-9127-4E57A64A396D Q37575709-0DFAD370-72A1-4A7B-8E57-EE2E7AE54966 Q37712297-46912E0E-2662-4EF8-9D39-983D42D59C6D Q37726433-42CBA81D-C22A-4D7E-B5DD-0ED619A981AB Q37805757-A86D93AE-32EB-4D7E-93FB-819E59B470A9 Q37969770-3467E98A-D674-4E1C-AA7B-9B058A8621AC Q37969851-2576903D-D4AB-4EE0-9B29-D0B87A162E88 Q38016943-C9AE6F75-5FB1-4037-8F8D-06984E6E29B6 Q38202816-E0805ACF-BC44-42F9-9E91-84512652B650 Q38393997-2D831415-EF3B-463F-909F-A2A89F37E361 Q38409621-A3D06525-BF8E-4D0C-A109-BC470E637A2B Q38835268-C1CA60D5-FEEF-4AC6-9D68-39E8E08CDF10 Q39043677-349B6870-3984-489F-86AA-85D0396595AC Q39093841-AA54A43C-BFB2-4BEA-84B3-114F567148D4 Q42178970-B3E3D55A-09A5-455A-A58E-BAD847F9909C Q43296440-90C23861-1A35-4752-AF3C-DF6D4670AA5F

P2860

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.

http://www.wikidata.org/entity/Q27863360

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Pharmacogenetic profiling in p ...... rst-line FOLFIRI chemotherapy.

@ast

Pharmacogenetic profiling in p ...... rst-line FOLFIRI chemotherapy.

@en

Pharmacogenetic profiling in p ...... rst-line FOLFIRI chemotherapy.

@nl

type

label

Pharmacogenetic profiling in p ...... rst-line FOLFIRI chemotherapy.

@ast

Pharmacogenetic profiling in p ...... rst-line FOLFIRI chemotherapy.

@en

Pharmacogenetic profiling in p ...... rst-line FOLFIRI chemotherapy.

@nl

altLabel

Pharmacogenetic profiling in p ...... irst-line FOLFIRI chemotherapy

@en

prefLabel

Pharmacogenetic profiling in p ...... rst-line FOLFIRI chemotherapy.

@ast

Pharmacogenetic profiling in p ...... rst-line FOLFIRI chemotherapy.

@en

Pharmacogenetic profiling in p ...... rst-line FOLFIRI chemotherapy.

@nl

P1433

Q27863360-75149B7A-FCF0-4ECF-8EF8-C1BB0AC5525A

P1476

Q27863360-2911CD89-0663-47BA-B792-A7E9AE916F9D

P2093

Q27863360-0DDCA019-037C-4C60-8FA5-5E5280AC2095

Q27863360-26F785C2-681E-4E95-A8FC-25C4371A4826

Q27863360-3C338FE7-929E-47BD-A39D-492961416CBE

Q27863360-417730A6-58F6-4E43-B3A6-9A412A3428EB

Q27863360-51DBD15F-C3B2-4065-858E-A509C239528F

Q27863360-567D4F0E-1F50-47C2-9E6F-1033698F942B

Q27863360-648D3DB6-A49B-4C6B-87ED-7FB404E2FF84

Q27863360-68EE45F8-EE36-408B-9147-6312D60A4388

Q27863360-6C93EA27-B7D4-4D01-A406-22691E2DB39F

Q27863360-707BC1A9-37C1-4EB6-B7D8-A0AB5392C820

P2860

Q27863360-0572F28F-975A-43DB-813A-2791DA73E682

Q27863360-0625D678-8C48-4A5D-BC57-43313F06118A

Q27863360-186DC5A8-CE00-41A4-AC08-223CBE08C03D

Q27863360-25C1AAAF-50B1-447C-B984-D1BEFA82E0A2

Q27863360-302B44DE-B7BE-47FE-AAA0-4906616DE50D

Q27863360-317E9E5B-EAD4-4D73-9044-61F985DE708C

Q27863360-405343FB-790B-4B3B-A2BF-A72C75A94EAC

Q27863360-40C06867-F5F5-4EDB-8F72-B44B754E1218

Q27863360-4251CE0A-94B4-49CD-900F-EEDEF96DBE9E

Q27863360-435824F8-0C19-41AD-92E1-6C3B46460570

P2888

Q27863360-27C36006-60A1-4D6A-853F-C8C1E6723F73

P304

Q27863360-C3A37273-C9D6-42F5-8025-8FAF31886196

P31

Q27863360-9E6A6AD9-F91A-465F-9B25-6BC270DDC9D8

P3181

Q27863360-1BFFE0DD-CAFC-4408-AE2D-9AC297741C65

P356

Q27863360-5C1B617F-FB7B-4EF6-9456-5796BC2486A8

P407

Q27863360-9854DC18-231A-457C-9088-896025CDC932

P433

Q27863360-99179D95-A4E7-42EC-B28A-A57658216C3D

P478

Q27863360-9DF43356-0E11-46FE-8C26-FBBBB5CA14CC

P577

Q27863360-7C4DE446-E1D4-4C22-8D3A-37B8D3D312E6

P5875

Q27863360-5C330059-680B-44D0-B2A6-B6D187186A89

P6179

Q27863360-4ED74399-332F-48E2-8B35-59D694777553

P698

Q27863360-E09866A6-7E6E-4B75-8E5C-46E56C856917

P921

Q27863360-0CB95547-0CE6-456A-A242-7CAF3FB947C4

Q27863360-60FF79BD-1D24-4AA8-8951-CDC7C0435272

Q27863360-CCA4E6AE-F2A9-4F5A-BEA1-FC2A96B7CE82

P3181

P356

P1433

The Pharmacogenomics Journal

P1476

Pharmacogenetic profiling in p ...... rst-line FOLFIRI chemotherapy.

@en

P2093

A Falcone

http://www.w3.org/2001/XMLSchema#string

A Fontana

http://www.w3.org/2001/XMLSchema#string

A Ruzzo

http://www.w3.org/2001/XMLSchema#string

D Mari

http://www.w3.org/2001/XMLSchema#string

D Santini

http://www.w3.org/2001/XMLSchema#string

E Canestrari

http://www.w3.org/2001/XMLSchema#string

E T Menichetti

http://www.w3.org/2001/XMLSchema#string

E Testa

http://www.w3.org/2001/XMLSchema#string

F Andreoni

http://www.w3.org/2001/XMLSchema#string

F Graziano

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Topoisomerase I inhibitors: camptothecins and beyond

Molecular determinants of irinotecan efficacy.

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

The role of ABC transporters in clinical practice.

Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters.

Polymorphisms in DNA repair and environmental interactions.

Cancer pharmacogenetics.

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis.

P2888

P304

278-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3393939

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.TPJ.6500463

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6287704

http://www.w3.org/2001/XMLSchema#string

P6179

1011787763

http://www.w3.org/2001/XMLSchema#string

P698

17549067

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer